Stocks · Healthcare · Medical - Healthcare Information Services
Omada Health OMDA
$20.37 -0.20% Close, Oct 2, 2026 · NASDAQ · Market cap $1.21B
Strong growthHigh quality
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -0.1% from -13.5% a year earlier.
- Revenue over the last four quarters was $309.8M, up 47.6% from a year earlier.
- The diluted share count rose 11.6% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 18%
- Revenue growth, 3-year CAGRTop 15%
- Revenue growth accelerationBottom 36%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 32%
- Gross marginTop 45%
- Operating marginTop 42%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Bottom 46%
- Net debt / EBITDA (lower is better)Top 4%
- Interest coverTop 48%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 30%
- Free-cash-flow yieldTop 30%
- EBITDA / enterprise valueTop 34%
- Sales / enterprise valueTop 41%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 37%
- 6-month returnTop 16%
- 1-year return vs S&P 500Bottom 36%
- Distance from 52-week highTop 38%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 15%
- Share of analysts rating BuyTop 36%
- Upside to consensus price targetBottom 32%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 37%
- Maximum drawdown, 3 yearsTop 34%
- Beta vs S&P 500 (lower is better)Bottom 12%
- Net debt / EBITDA (lower is better)Top 4%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 49.4% | 47.6% | ↓ |
| Gross margin | 63.1% | 68.2% | ↑ |
| Operating margin | -13.5% | -0.1% | ↑ |
| FCF margin | -11.1% | 7.3% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 47.6% | 49.4% | ↓ | Top 18% |
| Gross margin | 68.2% | 63.1% | ↑ | Top 45% |
| Operating margin | -0.1% | -13.5% | ↑ | Top 42% |
| Net margin | 1.4% | -15.4% | ↑ | — |
| Free-cash-flow margin | 7.3% | -11.1% | ↑ | — |
| Return on invested capital | -0.2% | — | Top 32% | |
| Revenue growth, 3-year CAGR | 42.9% | — | Top 15% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -5.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 5.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +22.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -18.86×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.2×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.35%
- Shareholder yield
- -1.35%
- Share count change, 1 year
- +11.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 7, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 5
- Beats in the last 8 reports
- 5 of 6
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +0.0%
- Positive 20 days after report
- 3 of 5
Analysts
- Consensus price target
- $25.88
- Target vs current price
- +27.0%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 85%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +141.2% | +2.3% | +24.8% | +22.0% | — |
| May 7, 2026 | +112.5% | +3.4% | +1.1% | +14.8% | +29.3% |
| Mar 5, 2026 | +333.3% | +0.6% | +1.6% | -6.7% | +32.9% |
| Nov 6, 2025 | +40.0% | -6.1% | -7.9% | -25.4% | -43.4% |
| Aug 7, 2025 | +10.0% | +0.1% | +3.3% | +22.0% | +24.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $0.15 | $0.06 | +141.2% | $87.8M |
| May 7, 2026 | $0.01 | -$0.08 | +112.5% | $78.0M |
| Mar 5, 2026 | $0.13 | $0.03 | +333.3% | $75.8M |
| Nov 6, 2025 | -$0.06 | -$0.10 | +40.0% | $68.0M |
| Aug 7, 2025 | -$0.09 | -$0.10 | +10.0% | $61.4M |
| May 9, 2025 | -$0.13 | -$0.12 | -9.9% | $55.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 323.3× | — | — | Top 30% |
| P/E (forward) | 62.0× | — | — | — |
| EV / EBITDA | 84.2× | — | — | Top 34% |
| EV / Sales | 3.19× | — | — | Top 41% |
| Free-cash-flow yield | 1.88% | — | — | Top 30% |
| Earnings yield | 0.31% | — | — | Top 30% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 74
- 50-day average slope (20 days)
- -3.7%
- 200-day average slope (20 days)
- +1.8%
- Distance from 50-day average
- -6.4%
- Distance from 200-day average
- +17.9%
- RSI (14)
- 45.8
- Relative volume
- 0.82×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 62.5%
- Volatility vs own 5-year history
- 75th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.06
- Correlation with S&P 500
- 0.35
- Current drawdown from 1-year high
- -23.9%
- Maximum drawdown, 3 years
- -59.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Oct 28, 2025 | Feb 11, 2026 | -59.2% | 72 days | Not yet recovered |
| Jun 6, 2025 | Jun 23, 2025 | -35.4% | 10 days | 46 days (Aug 27, 2025) |
| Sep 5, 2025 | Sep 10, 2025 | -11.1% | 3 days | 24 days (Oct 14, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.21B
- P/E (TTM)
- 323.3
- EPS, diluted (TTM)
- $0.06
- Revenue (TTM)
- $309.8M
- 52-week range
- $10.28 – $26.92
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $89.2M | $122.8M | $169.8M | $260.2M |
| Gross profit | $42.8M | $70.0M | $102.9M | $170.9M |
| Operating income | -$72.3M | -$66.0M | -$43.7M | -$12.0M |
| Net income | -$72.5M | -$67.5M | -$47.1M | -$12.8M |
| EPS (diluted) | -$1.30 | -$1.21 | -$0.85 | -$0.22 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.5M | $48.0M | $55.0M | $61.4M | $68.0M | $75.8M | $78.0M | $87.8M |
| Net income | -$9.2M | -$8.2M | -$9.4M | -$5.3M | -$3.2M | $5.2M | -$3.0M | $5.3M |
| EPS (diluted) | -$0.17 | -$0.15 | -$0.17 | -$0.09 | -$0.05 | $0.09 | -$0.05 | $0.08 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Operating cash flow | -$69.0M | -$49.7M | -$34.2M | $18.3M |
| Capital expenditure | -$2.7M | -$2.9M | -$3.9M | -$1.3M |
| Free cash flow | -$71.7M | -$52.7M | -$38.0M | $16.9M |
| Dividends paid | $0 | $0 | $0 | $0 |
| Net share buybacks | $1.7M | $1.8M | $3.3M | $169.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $221.7M
- Total assets
- $328.2M
- Total liabilities
- $75.5M
- Total debt
- $0
- Net debt
- -$221.7M
- Shareholders’ equity
- $252.7M
As of Jun 30, 2026 (filed Aug 7, 2026).
Short interest
- Shares sold short
- 7,470,777
- Days to cover
- 5.93
- Change vs previous report
- +30.1%
FINRA short interest, settlement date Sep 15, 2026.